Vaccinex to present ActivMAb platform and pepinemab PDAC study at two conferences

VACCINEX, INC.

Presentation at CHI's DOT Conference on Sept 28: new ActivMAb application for multi-pass membrane proteins including CXCR5.
Poster on Phase 1b/2a pepinemab + avelumab in chemotherapy-refractory metastatic PDAC at AACR Pancreatic Cancer conference on Sept 29.
Dr. Ernest Smith to present at DOT; Dr. Luis Ruffolo of University of Rochester presents the PDAC poster.
Poster will be available on Vaccinex website under 'Investors/Presentations' starting Sept 27 at 5:30 pm ET.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.